Parametrica Management’s Fate Therapeutics FATE Stock Holding History

Parametrica Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$49.9K	Hold	18,472	–	–	0.04%	20
2026 Q1	$22.2K	Hold	18,472	–	–	0.03%	20
2025 Q4	$18.2K	Hold	18,472	–	–	0.03%	22
2025 Q3	$23.3K	Hold	18,472	–	–	0.04%	22
2025 Q2	$20.7K	Hold	18,472	–	–	0.04%	26
2025 Q1	$14.6K	Hold	18,472	–	–	0.02%	22
2024 Q4	$30.5K	Hold	18,472	–	–	0.04%	64
2024 Q3	$64.7K	Hold	18,472	–	–	0.08%	61
2024 Q2	$60.6K	Hold	18,472	–	–	0.08%	21
2024 Q1	$136K	Hold	18,472	–	–	0.2%	21
2023 Q4	$69.1K	Hold	18,472	–	–	0.11%	27
2023 Q3	$39.2K	Hold	18,472	–	–	0.07%	30
2023 Q2	$87.9K	Hold	18,472	–	–	0.17%	27
2023 Q1	$105K	Sell	18,472 -13,782	-43%	-$83.2K	0.19%	23
2022 Q4	$325K	Buy	32,254 +18,089	+128%	+$340K	0.67%	28
2022 Q3	$318K	Sell	14,165 -724	-5%	-$20.9K	0.65%	37
2022 Q2	$371K	Buy	14,889 +2,794	+23%	+$77.1K	0.4%	65
2022 Q1	$469K	Sell	12,095 -4,971	-29%	-$192K	0.35%	59
2021 Q4	$999K	Sell	17,066 -2,844	-14%	-$161K	0.99%	31
2021 Q3	$1.18M	Buy	+19,910	New	+$1.56M	0.88%	31
2021 Q1	–	Sell	-2,752	Closed	-$250K	–	190
2020 Q4	$250K	Buy	+2,752	New	+$171K	0.15%	124

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Parametrica Management's FATE Position: Q2 2026 in Review

Parametrica Management held its Fate Therapeutics (FATE) position steady in Q2 2026 at 18,472 shares worth $49.9K. The position accounts for 0.04% of the portfolio, ranked #20.

Parametrica Management first reported a position in FATE in Q4 2020 and has held it in 21 quarters since. The position peaked at $1.18M in Q3 2021. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

Parametrica Management held 18,472 shares of Fate Therapeutics worth $49.9K as of Q2 2026.
Parametrica Management left its Fate Therapeutics share count unchanged in Q2 2026.
Fate Therapeutics made up 0.04% of Parametrica Management's portfolio in Q2 2026, its #20 holding.
Parametrica Management first reported a position in Fate Therapeutics in Q4 2020 and has held it in 21 quarters since.
Parametrica Management's Fate Therapeutics position peaked at $1.18M in Q3 2021.
156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Parametrica Management's 13F filing for Q2 2026, filed 12 Aug 2026.